VCB-1204 / Vaxcell-Bio Therap - LARVOL DELTA

Dual PD-L1/EphA2 tandem CAR-T cells achieve potent and safe anti-tumor effects across multiple solid tumor models (ESMO 2025) - "Conclusions PD-L1-EphA2-CD28 dual CAR-T cells exhibit robust and broad anti-tumor efficacy across diverse solid tumor models with a favorable safety profile. These findings support the therapeutic potential of dual-targeting CAR-T cell strategies for effective and safe treatment of PD-L1 and EphA2-expressing malignancies."

CAR T-Cell Therapy • IO biomarker • Preclinical • Hematological Malignancies • Oncology • Solid Tumor • EPHA2 • GZMB • IFNG • PD-L1 • TNFA

Vaxcell Bio's Dual-Target CAR-T Clinical Trial Selected by the National Cancer Center [Google translation] (HIT News) - "The research project title is 'Intermediate study for clinical entry of PD-L1/EphA2 dual-target CAR-T cell therapy for solid tumor treatment', and Paxel Bio signed an agreement with the National Cancer Center and will conduct the project jointly with Chonnam National University Hwasun Hospital, the medical institution, for 4 years and 6 months. The company aims to enter clinical trials using dual-target CAR-T immunotherapy for patients with solid tumors such as gastric cancer, ovarian cancer, and liver cancer."

Commercial • Gastric Cancer • Hepatocellular Cancer • Ovarian Cancer

Vaxcellbio wins hospital project for dual-target CAR-T clinical research (Korea Biomedical Review) - "The selected project...will be carried out over four years and six months in collaboration with the National Cancer Center and Chonnam National University Hwasun Hospital....The research aims to advance Vaxcellbio’s novel dual-target CAR-T immunotherapy into clinical studies for patients with gastric, ovarian, and liver cancers."

Clinical • Gastric Cancer • Hepatocellular Cancer • Ovarian Cancer

VaxCell-Bio partners with ProBio to accelerate CAR-related therapies development (Korea Biomedical Review) - "..the two companies plan to cooperate on the production of phase 1 clinical trial drugs and explore synergies in research (CDO) and manufacturing (CMO) for future next-generation gene therapy pipelines...'Through our partnership with VaxCell-Bio, ProBio will provide customized solutions in high-quality plasmid and viral vector production, CMC development, and GMP manufacturing.'....Leveraging VaxCell-Bio’s deep expertise in NK cell therapy and CAR therapy development, this collaboration is expected to significantly advance their pipeline and introduce innovative therapies to the market, delivering cutting-edge treatments to patients more rapidly, Liu added."

Licensing / partnership • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Small Cell Lung Cancer • Solid Tumor

Vaxel Bio, Anti-PD-L1 CAR-T Treatment Patent Registration [Google translation] (HIT News) - "Vaxcell Bio...announced on the 14th that it has completed patent registration for 'VaxCAR-001', a chimeric antigen receptor T cell (CAR-T) treatment targeting PD-L1, an immune checkpoint protein....'We will further accelerate the development of a dual-target CAR-T treatment targeting PD-L1 and EphA2 for solid cancers. Following domestic patents, we will secure international patents to seek entry into the global market and technology transfer.'"

Patent • Pipeline update • Oncology • Solid Tumor

VaxCell-Bio secures KDDF funding to develop solid tumor dual-target CAR-T therapy (Korea Biomedical Review) - "VaxCell-Bio...said it signed an agreement with the Korea Drug Development Fund (KDDF) last Friday to receive funding for the R&D of a solid tumor dual-targeting chimeric antigen receptor T cell (CAR-T) therapy targeting programmed death ligand (PD-L1) and EPH Receptor A2 (EphA2), prevalent biomarkers in refractory solid tumors, from April 2024 to December 2025....VaxCell-Bio said its upgraded CAR-T therapy — based on its monobody platform — simultaneously targets EphA2, a tumor marker, and PD-L1, an immune checkpoint inhibitor."

Licensing / partnership • Oncology • Solid Tumor

Vaxcell Bio announces final results of phase 2a of ‘hepatocellular cancer treatment’ at BioUSA [Google translation] (HIT News) - P2a | N=17 | NCT05040438 | Sponsor: Vaxcell Bio, Co., Ltd. | "Vaxcell Bio...participated in the '2024 Bio International Convention...In the case of Vax-NK/HCC, a treatment for hepatocellular carcinoma, an objective response rate of 68.75% was recorded in the final report of phase 2a clinical trial as a result of combination therapy with standard treatment HAIC. This figure is more than twice as high as the existing standard treatment, atezolizumab and bevacizumab combination therapy at 30%, sorafenib at 11%, and HAIC alone at 30%....PD-L1·EphA2 dual-target CAR-T solid cancer treatment targeting solid cancers such as ovarian cancer, stomach cancer, and pancreatic cancer has attracted attention from related industries as it is effective in blocking gastric evasion of cancer cells with two target cancer markers instead of one. Vaxcell Bio applied for a patent for PD-L1·EphA2 dual-target CAR-T solid tumor treatment in November last year..."

P2a data • Patent • Preclinical • Gastric Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Hepatocellular Cancer • Liver Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor